Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells

被引：60

作者：

Ersvaer E. ^{[1
]}

Liseth K. ^{[2
]}

Skavland J. ^{[1
]}

Gjertsen B.T. ^{[1
,2
]}

Bruserud Ø. ^{[1
,2
]}

机构：

[1] Institute of Medicine, University of Bergen, Bergen

[2] Department of Medicine, Haukeland University Hospital, Bergen

来源：

BMC Immunology | / 11卷 / 1期

关键词：

Acute Myeloid Leukemia; TREG Cell; Acute Myeloid Leukemia Patient; Acute Myeloid Leukemia Cell; Untreated Disease;

D O I：

10.1186/1471-2172-11-38

中图分类号：

学科分类号：

摘要：

Background: Several observations suggest that immunological events early after chemotherapy, possibly during the period of severe treatment-induced cytopenia, are important for antileukemic immune reactivity in acute myeloid leukemia (AML). We therefore investigated the frequencies of various T cell subsets (TC1, TH1, TH17) and CD25+ FoxP3+ TREG cells in AML patients with untreated disease and following intensive chemotherapy.Results: Relative levels of circulating TC1 and TH1 cells were decreased in patients with severe chemotherapy-induced cytopenia, whereas TH17 levels did not differ from healthy controls. Increased levels of regulatory CD25+ FoxP3+ T cells were detected in AML patients with untreated disease, during chemotherapy-induced cytopenia and during regeneration after treatment. TH17 and TH1 levels were significantly higher in healthy males than females, but this gender difference was not detected during chemotherapy-induced cytopenia. Finally, exogenous IL17-A usually had no or only minor effects on proliferation of primary human AML cells.Conclusions: We conclude that the effect of intensive AML chemotherapy differ between circulating T cell subsets, relative frequencies of TH17 cells are not affected by chemotherapy and this subset may affect AML cells indirectly through their immunoregulatory effects but probably not through direct effects of IL17-A. © 2010 Ersvaer et al; licensee BioMed Central Ltd.

引用

共 42 条

[1]

Smith M., Barnett M., Bassan R., Gatta G., Tondini C., Kern W., Adult acute myeloid leukaemia, Crit Rev Oncol Hematol, 50, pp. 197-222, (2004)

[2]

Williams K.M., Hakim F.T., Gress R.E., T cell immune reconstitution following lymphodepletion, Semin Immunol, 19, pp. 318-330, (2007)

[3]

Auletta J.J., Lazarus H.M., Immune restoration following hematopoietic stem cell transplantation: an evolving target, Bone Marrow Transplant, 35, pp. 835-857, (2005)

[4]

Behl D., Porrata L.F., Markovic S.N., Letendre L., Pruthi R.K., Hook C.C., Tefferi A., Elliot M.A., Kaufmann S.H., Mesa R.A., Et al., Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia, Leukemia, 20, pp. 29-34, (2006)

[5]

Porrata L.F., Litzow M.R., Tefferi A., Letendre L., Kumar S., Geyer S.M., Markovic S.N., Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia, Leukemia, 16, pp. 1311-1318, (2002)

[6]

Parkman R., Cohen G., Carter S.L., Weinberg K.I., Masinsin B., Guinan E., Kurtzberg J., Wagner J.E., Kernan N.A., Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation, Biol Blood Marrow Transplant, 12, pp. 919-927, (2006)

[7]

Kim D.H., Sohn S.K., Won D.I., Lee N.Y., Suh J.S., Lee K.B., Rapid helper T-cell recovery above 200 × 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation, Bone Marrow Transplant, 37, pp. 1119-1128, (2006)

[8]

Obeid M., Tesniere A., Panaretakis T., Tufi R., Joza N., van Endert P., Ghiringhelli F., Apetoh L., Chaput N., Flament C., Et al., Ecto-calreticulin in immunogenic chemotherapy, Immunol Rev, 220, pp. 22-34, (2007)

[9]

Szczepanski M.J., Szajnik M., Czystowska M., Mandapathil M., Strauss L., Welsh A., Foon K.A., Whiteside T.L., Boyiadzis M., Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia, Clin Cancer Res, 15, pp. 3325-3332, (2009)

[10]

Wang X., Zheng J., Liu J., Yao J., He Y., Li X., Yu J., Yang J., Liu Z., Huang S., Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients, Eur J Haematol, 75, pp. 468-476, (2005)

← 1 2 3 4 5 →